Haemodynamic effects of Milrinone in patients with heart failure and preserved ejection fraction (HFPEF)

Phase 2

Recruiting

• Conditions: Heart failure; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12614000727640
• Lead Sponsor: Alfred Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-07-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

Adults greater than or equal to 18 years of age, AND
Symptoms of HF (NYHA II-III) AND
Normal ejection fraction (LVEF equal to and more than 45%) with evidence of diastolic dysfunction as prescribed by ESC Working Group 15 (resting PCWP more than 12; E/e’ more than 15 or Eand e prime more than 8 and
and NT-BNP more than 220)

Exclusion Criteria

Other cause for dyspnoea including moderate or severe valvular HD and pulmonary hypertension with PVR more than 4 Wood Units
Body mass index (BMI) more than 35 kg/m2
History of stress-induced syncope or ventricular tachycardia during exercise
Unstable coronary artery disease
Symptoms and signs of congestive heart failure at rest (NYHA IV)
Unable to perform exercise test

Study & Design

• Study Type: Interventional
• Study Design: Not specified